| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study |
179 |
| Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission |
84 |
| Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial |
78 |
| Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis |
72 |
| Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study |
58 |
| A global scientific strategy to cure hepatitis B |
54 |
| Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial |
53 |
| Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase multicentre trial |
48 |
| Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis |
44 |
| The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
40 |
| Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study |
38 |
| Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study |
37 |
| Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis |
33 |
| Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial |
33 |
| The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 |
33 |
| Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial |
32 |
| Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial |
32 |
| Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study |
31 |
| Changes in colorectal cancer incidence in seven high-income countries: a population-based study |
30 |
| Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial |
30 |
| Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series |
30 |
| Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials |
28 |
| Artificial intelligence and computer-aided diagnosis in colonoscopy: current evidence and future directions |
26 |
| Hartmann's procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or faecal peritonitis (LADIES): a multicentre, parallel-group, randomised, open-label, superiority trial |
26 |
| Viral hepatitis in children and adolescents 2 Hepatitis C virus infection in children and adolescents |
25 |
| Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial |
24 |
| Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study |
24 |
| Safety and effectiveness of SGM- a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study |
24 |
| Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe |
23 |
| Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial |
23 |
| Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial |
23 |
| Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial |
22 |
| Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis |
21 |
| Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase open-label, randomised controlled trial |
21 |
| Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial |
21 |
| Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase randomised controlled trial |
20 |
| The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study |
20 |
| Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial |
20 |
| Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study |
19 |
| Non-alcoholic fatty liver disease and the interface between primary and secondary care |
19 |
| Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies |
18 |
| Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial |
18 |
| Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study |
18 |
| Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study |
18 |
| Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study |
18 |
| Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study |
17 |
| Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial |
17 |
| Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-6): an open-label, multicentre, phase 3b trial |
16 |
| Viral hepatitis in children and adolescents 1 Hepatitis B virus infection in children and adolescents |
16 |
| Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial |
16 |
| Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis |
15 |
| Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score |
15 |
| Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial |
15 |
| Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial |
14 |
| Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series |
14 |
| Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west |
14 |
| Resolving gastric cancer aetiology: an update in genetic predisposition |
14 |
| A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus |
14 |
| Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus |
14 |
| Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand |
14 |
| Microscopic colitis: pathophysiology and clinical management |
14 |
| Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study |
14 |
| An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project |
13 |
| Porto-sinusoidal vascular disease: proposal and description of a novel entity |
13 |
| Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study |
13 |
| Home-based versus office-based biofeedback therapy for constipation with dyssynergic defecation: a randomised controlled trial |
12 |
| Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase non-inferiority, randomised trial |
12 |
| Pathophysiology, diagnosis, and management of opioid-induced constipation |
11 |
| Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial |
11 |
| Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01) |
11 |
| Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension |
11 |
| Comorbidities in inflammatory bowel disease: a call for action |
11 |
| Effects of enteral nutrition on gastrointestinal function in patients who are critically ill |
11 |
| Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study |
11 |
| Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study |
11 |
| The association between dietary fibre deficiency and high-income lifestyle-associated diseases: Burkitt's hypothesis revisited |
11 |
| Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase multicentre trial |
11 |
| Efficacy of individual and group hypnotherapy in irritable bowel syndrome (IMAGINE): a multicentre randomised controlled trial |
10 |
| The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment |
10 |
| Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial |
10 |
| Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses |
10 |
| Advances in IgG4-related pancreatobiliary diseases |
9 |
| HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies |
9 |
| Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study |
9 |
| Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial |
8 |
| Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial |
8 |
| Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial |
8 |
| Inhibition of EGFR, HER and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial |
8 |
| Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis |
8 |
| Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development |
8 |
| Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials |
8 |
| Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure |
7 |
| Mass migration to Europe: an opportunity for elimination of hepatitis B virus? |
7 |
| Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial |
7 |
| Differential diagnosis of inflammatory bowel disease: imitations and complications |
7 |
| Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study |
7 |
| Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses |
7 |
| Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease |
7 |
| Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial |
7 |
| Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial |
7 |
| Post-imaging colorectal cancer or interval cancer rates after CT colonography: a systematic review and meta-analysis |
7 |
| Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study |
7 |
| Cirrhosis with ascites in the last year of life: a nationwide analysis of factors shaping costs, health-care use, and place of death in England |
6 |
| Simplified versus standard regimen for focal radiofrequency ablation of dysplastic Barrett's oesophagus: a multicentre randomised controlled trial |
6 |
| Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial |
6 |
| Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial |
6 |
| Safely reprocessing duodenoscopes: current evidence and future directions |
6 |
| Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial |
6 |
| Perioperative lipid-enriched enteral nutrition versus standard care in patients undergoing elective colorectal surgery (SANICS II): a multicentre, double-blind, randomised controlled trial |
6 |
| Laparoscopic versus open adhesiolysis for adhesive small bowel obstruction (LASSO): an international, multicentre, randomised, open-label trial |
6 |
| Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial |
5 |
| Stretching the boundaries for liver transplant in the 21st century |
5 |
| Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study |
5 |
| Unmet needs and new models for future trials in autoimmune hepatitis |
4 |
| Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial |
4 |
| Feasibility and economic assessment of chromocolonoscopy for detection of proximal serrated neoplasia within a population-based colorectal cancer screening programme (CONSCOP): an open-label, randomised controlled non-inferiority trial |
3 |
| Management of metabolic syndrome and cardiovascular risk after liver transplantation |
3 |
| Idiopathic recurrent acute pancreatitis |
3 |
| Effect of diagnosis, surveillance, and treatment of Barrett's oesophagus on health-related quality of life |
3 |
| Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial |
3 |
| Molecular radionuclide imaging of pancreatic neoplasms |
3 |
| Improving the quality of surveillance colonoscopy in inflammatory bowel disease |
3 |
| Place of death and factors associated with hospital death in patients who have died from liver disease in England: a national population-based study |
2 |
| Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial |
2 |
| Submucosal surgery: novel interventions in the third space |
2 |
| Optimal dilation time for combined small endoscopic sphincterotomy and balloon dilation for common bile duct stones: a multicentre, single-blinded, randomised controlled trial |
2 |
| Diffusion-weighted MRI in inflammatory bowel disease |
2 |
| Emerging optical methods for endoscopic surveillance of Barrett's oesophagus |
2 |
| Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full- dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial |
2 |
| Factors affecting adenoma detection rate in a national flexible sigmoidoscopy screening programme: a retrospective analysis |
2 |
| Chronic constipation: new insights, better outcomes? |
1 |
| Use of tumour necrosis factor-alpha inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study |
1 |
| Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1 |
1 |
| Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial |
1 |
| Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme |
1 |
| A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score |
0 |
| Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial |
0 |
| Liver disease in the young adult: the challenges and rewards |
0 |
